PL377740A1 - Kompozycje farmaceutyczne ze zmodyfikowaną zaróbką - Google Patents

Kompozycje farmaceutyczne ze zmodyfikowaną zaróbką

Info

Publication number
PL377740A1
PL377740A1 PL377740A PL37774003A PL377740A1 PL 377740 A1 PL377740 A1 PL 377740A1 PL 377740 A PL377740 A PL 377740A PL 37774003 A PL37774003 A PL 37774003A PL 377740 A1 PL377740 A1 PL 377740A1
Authority
PL
Poland
Prior art keywords
pharmaceutical compositions
modified vehicle
modified
vehicle
pharmaceutical
Prior art date
Application number
PL377740A
Other languages
English (en)
Inventor
Ondrej Hendl
Susan Marie Machkovech
Niki Ann Waldron
Nancy Jean Britten
Dannette Marie Shaw
Alanta Lea Lary
Thomas Joseph Yellig
Original Assignee
Pharmacia & Upjohn Company Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32326579&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL377740(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia & Upjohn Company Llc filed Critical Pharmacia & Upjohn Company Llc
Publication of PL377740A1 publication Critical patent/PL377740A1/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
PL377740A 2002-11-19 2003-11-17 Kompozycje farmaceutyczne ze zmodyfikowaną zaróbką PL377740A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42768002P 2002-11-19 2002-11-19

Publications (1)

Publication Number Publication Date
PL377740A1 true PL377740A1 (pl) 2006-02-20

Family

ID=32326579

Family Applications (1)

Application Number Title Priority Date Filing Date
PL377740A PL377740A1 (pl) 2002-11-19 2003-11-17 Kompozycje farmaceutyczne ze zmodyfikowaną zaróbką

Country Status (18)

Country Link
US (1) US7659061B2 (pl)
EP (1) EP1569693B1 (pl)
JP (1) JP4656945B2 (pl)
KR (1) KR20050085037A (pl)
CN (2) CN103272243A (pl)
AR (1) AR042193A1 (pl)
AU (1) AU2003276594B2 (pl)
BR (1) BR0316310A (pl)
CA (1) CA2502025C (pl)
IL (1) IL168183A (pl)
MX (1) MXPA05005319A (pl)
NO (1) NO20051688L (pl)
NZ (1) NZ539923A (pl)
PL (1) PL377740A1 (pl)
RU (1) RU2401127C2 (pl)
TW (1) TWI267379B (pl)
WO (1) WO2004045646A1 (pl)
ZA (1) ZA200503040B (pl)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9943614B2 (en) 2008-06-17 2018-04-17 Brigham Young University Cationic steroid antimicrobial diagnostic, detection, screening and imaging methods
CN104053458B (zh) 2011-07-20 2016-07-20 布莱阿姆青年大学 包含洗脱塞拉集宁化合物的水凝胶材料
MX369385B (es) 2011-09-13 2019-11-07 Univ Brigham Young Productos para cicatrizar heridas tisulares.
US9694019B2 (en) 2011-09-13 2017-07-04 Brigham Young University Compositions and methods for treating bone diseases and broken bones
US9603859B2 (en) 2011-09-13 2017-03-28 Brigham Young University Methods and products for increasing the rate of healing of tissue wounds
EP2755661A1 (en) 2011-09-13 2014-07-23 Brigham Young University Compositions for treating bone diseases and broken bones
KR20140116111A (ko) 2011-12-21 2014-10-01 브라이엄 영 유니버시티 구강 관리 조성물
US9533063B1 (en) 2012-03-01 2017-01-03 Brigham Young University Aerosols incorporating ceragenin compounds and methods of use thereof
US10039285B2 (en) 2012-05-02 2018-08-07 Brigham Young University Ceragenin particulate materials and methods for making same
EP2908826A1 (en) 2012-10-17 2015-08-26 Brigham Young University Treatment and prevention of mastitis
JP6294352B2 (ja) 2013-01-07 2018-03-14 ブリガム・ヤング・ユニバーシティBrigham Young University 細胞増殖を減少させ、ある特定の疾患を治療する方法
US10568893B2 (en) 2013-03-15 2020-02-25 Brigham Young University Methods for treating inflammation, autoimmune disorders and pain
US11524015B2 (en) 2013-03-15 2022-12-13 Brigham Young University Methods for treating inflammation, autoimmune disorders and pain
WO2014151411A1 (en) 2013-03-15 2014-09-25 Brigham Young University Methods for treating inflammation, autoimmune disorders and pain
US9387215B2 (en) 2013-04-22 2016-07-12 Brigham Young University Animal feed including cationic cholesterol additive and related methods
US11690855B2 (en) 2013-10-17 2023-07-04 Brigham Young University Methods for treating lung infections and inflammation
US20150203527A1 (en) 2014-01-23 2015-07-23 Brigham Young University Cationic steroidal antimicrobials
CA2844321C (en) 2014-02-27 2021-03-16 Brigham Young University Cationic steroidal antimicrobial compounds
US9867836B2 (en) 2014-03-13 2018-01-16 Brigham Young University Lavage and/or infusion using CSA compounds for increasing fertility in a mammal
US10220045B2 (en) 2014-03-13 2019-03-05 Brigham Young University Compositions and methods for forming stabilized compositions with reduced CSA agglomeration
US9931350B2 (en) 2014-03-14 2018-04-03 Brigham Young University Anti-infective and osteogenic compositions and methods of use
US9956164B2 (en) 2014-04-16 2018-05-01 Veyx-Pharma Gmbh Veterinary pharmaceutical composition and use thereof
US9686966B2 (en) 2014-04-30 2017-06-27 Brigham Young University Methods and apparatus for cleaning or disinfecting a water delivery system
US10238665B2 (en) 2014-06-26 2019-03-26 Brigham Young University Methods for treating fungal infections
US10441595B2 (en) 2014-06-26 2019-10-15 Brigham Young University Methods for treating fungal infections
US10227376B2 (en) 2014-08-22 2019-03-12 Brigham Young University Radiolabeled cationic steroid antimicrobials and diagnostic methods
US10155788B2 (en) 2014-10-07 2018-12-18 Brigham Young University Cationic steroidal antimicrobial prodrug compositions and uses thereof
US9527883B2 (en) 2015-04-22 2016-12-27 Brigham Young University Methods for the synthesis of ceragenins
US10370403B2 (en) 2015-04-22 2019-08-06 Brigham Young University Methods for the synthesis of ceragenins
US9434759B1 (en) 2015-05-18 2016-09-06 Brigham Young University Cationic steroidal antimicrobial compounds and methods of manufacturing such compounds
US10226550B2 (en) 2016-03-11 2019-03-12 Brigham Young University Cationic steroidal antimicrobial compositions for the treatment of dermal tissue
US10959433B2 (en) 2017-03-21 2021-03-30 Brigham Young University Use of cationic steroidal antimicrobials for sporicidal activity
US12186328B2 (en) 2019-05-23 2025-01-07 Brigham Young University Use of CSA compounds to stimulate stem cells and hair growth

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US110561A (en) * 1870-12-27 Improvement in children s carriages
US4297353A (en) 1980-08-04 1981-10-27 Sandoz, Inc. Non-irritating injectable dosage forms
HU196714B (en) * 1984-10-04 1989-01-30 Monsanto Co Process for producing non-aqueous composition comprising somatotropin
US5019395A (en) 1988-03-08 1991-05-28 Warner-Lambert Company Compositions with enhanced penetration
JP2856444B2 (ja) * 1989-07-28 1999-02-10 呉羽化学工業株式会社 ビタミンd▲下3▼代謝産物製剤
JP3078859B2 (ja) 1990-02-23 2000-08-21 武田薬品工業株式会社 安定な放出制御性製剤用コーティング剤
FR2692480B1 (fr) 1992-06-22 1995-12-08 Technico Flor Sa Nouvelles compositions cosmetiques ou alimentaires renfermant du copaiba.
KR100296810B1 (ko) 1993-03-12 2001-10-24 로렌스 티. 마이젠헬더 결정성세프티오퍼유리산
DE4340879A1 (de) 1993-12-01 1995-06-08 Horst P O Dr Wolf Arzneimittel zur Behandlung der Herzinsuffizienz
ATE252894T1 (de) 1995-01-05 2003-11-15 Univ Michigan Oberflächen-modifizierte nanopartikel und verfahren für ihre herstellung und verwendung
WO1997049402A1 (en) 1996-06-27 1997-12-31 Janssen Pharmaceutica N.V. Sustained release sufentanil compositions
US5736151A (en) * 1996-12-09 1998-04-07 Pharmacia & Upjohn Company Antibiotic oil suspensions
US6074657A (en) * 1997-03-20 2000-06-13 Pharmacia & Upjohn Company Administration of an injectable antibiotic in the ear of an animal
MXPA03002055A (es) * 2000-09-12 2004-12-13 Upjohn Co Composicion farmaceutica con excipiente modificado.
MXPA03002056A (es) * 2000-09-12 2003-07-24 Pharmacia & Upjohn Company Composicion farmaceutica con actividad de agua especifica.

Also Published As

Publication number Publication date
NO20051688L (no) 2005-08-02
NZ539923A (en) 2007-02-23
TW200427466A (en) 2004-12-16
MXPA05005319A (es) 2005-07-25
KR20050085037A (ko) 2005-08-29
BR0316310A (pt) 2005-09-27
EP1569693B1 (en) 2016-12-28
CA2502025C (en) 2013-07-02
JP2006514629A (ja) 2006-05-11
US20040170650A1 (en) 2004-09-02
US7659061B2 (en) 2010-02-09
RU2401127C2 (ru) 2010-10-10
IL168183A (en) 2010-04-29
EP1569693A1 (en) 2005-09-07
NO20051688D0 (no) 2005-04-05
AU2003276594A1 (en) 2004-06-15
TWI267379B (en) 2006-12-01
CN1713923A (zh) 2005-12-28
RU2005115131A (ru) 2005-10-27
WO2004045646A1 (en) 2004-06-03
ZA200503040B (en) 2006-09-27
CN103272243A (zh) 2013-09-04
AU2003276594B2 (en) 2009-01-08
CA2502025A1 (en) 2004-06-03
AR042193A1 (es) 2005-06-15
JP4656945B2 (ja) 2011-03-23

Similar Documents

Publication Publication Date Title
PL377740A1 (pl) Kompozycje farmaceutyczne ze zmodyfikowaną zaróbką
GB2389530B (en) Pharmaceutical compositions
AU2003291103A8 (en) Pharmaceutical composition
GB0218625D0 (en) Pharmaceutical compounds
IL164547A0 (en) Pharmaceutical composition
AU2003276549A8 (en) Pharmaceutical compositions containing a biguanide-glitazone combination
GB2391473B (en) Pharmaceutical compositions
IL165878A0 (en) Pharmaceutical composition
GB0215775D0 (en) Pharmaceutical compounds
HU0302441D0 (en) Pharmaceutical compositions having antibiothic effect
GB0229258D0 (en) Medicinal compositions
GB0213481D0 (en) Pharmaceutical compositions
GB0206505D0 (en) Pharmaceutical combination
AU2003208621A1 (en) A pharmaceutical composition
GB0201520D0 (en) Pharmaceutical uses
PL373409A1 (pl) Kombinacja farmaceutyczna
GB0204392D0 (en) Pharmaceutical compound
PL370907A1 (pl) Kompozycje farmaceutyczne
GB0217703D0 (en) Pharmaceutical composition
GB0225880D0 (en) Pharmaceutical compositions
GB0221068D0 (en) Pharmaceutical compositions
GB0210663D0 (en) Pharmaceutical compositions
GB0209379D0 (en) Pharmaceutical compositions
GB0214491D0 (en) Pharmaceutical composition
GB0211448D0 (en) Pharmaceutical composition